We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+31.46%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$91.5M
AUM Growth
+$23.2M
Cap. Flow
+$1.78M
Cap. Flow %
1.95%
Top 10 Hldgs %
59.03%
Holding
57
New
10
Increased
4
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
STXS icon
Stereotaxis
STXS
+$4.59M
2
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$2.74M
3
PLX icon
Protalix BioTherapeutics
PLX
+$1.59M
4
HSTO
Histogen Inc. Common Stock
HSTO
+$1.07M
5
KBIO
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
+$969K

Top Sells

Rank Stock Value
1
NVDQ
Novadaq Technologies Inc.
NVDQ
+$2.52M
2
DYAX
DYAX CORPORATION
DYAX
+$2.28M
3
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$821K
4
BEAT
BioTelemetry, Inc.
BEAT
+$734K
5
INFU icon
InfuSystem Holdings
INFU
+$707K

Sector Composition

Rank Sector Weight
1 Healthcare 66.11%
2 Miscellaneous 32.25%
3 Financials 1.25%
4 Communication Services 0.38%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$14.1M 15.43%
102,128
– –
PLX icon
2
Protalix BioTherapeutics
PLX
$205M
$5.34M 5.83%
117,844
+31,033
+36% +$1.59M
STXS icon
3
Stereotaxis
STXS
$145M
$5.28M 5.77%
2,171,905
+1,868,439
+616% +$4.59M
ATRC icon
4
AtriCure
ATRC
$2.47B
$5.25M 5.73%
477,701
– –
NVDQ
5
DELISTED
Novadaq Technologies Inc.
NVDQ
$4.71M 5.14%
284,041
-177,321
-38% -$2.52M
PODD icon
6
Insulet
PODD
$10.1B
$4.53M 4.95%
124,981
– –
WINT
7
DELISTED
Windtree Therapeutics Inc
WINT
$3.97M 4.34%
144,689
+20,856
+17% +$506K
NXTM
8
DELISTED
NxStage Medical Inc.
NXTM
$3.31M 3.62%
251,654
– –
AMPE
9
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$3.19M 3.49%
+1,419
New +$2.74M
BEAT
10
DELISTED
BioTelemetry, Inc.
BEAT
$3.06M 3.34%
308,565
-93,223
-23% -$734K
GIVN
11
DELISTED
GIVEN IMAGING LTD
GIVN
$3.01M 3.28%
156,320
– –
ARIA
12
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.74M 2.99%
148,915
-42,300
-22% -$821K
CRIS icon
13
Curis
CRIS
$3.61M
$2.36M 2.58%
265
-10
-4% -$80.8K
NSPR icon
14
InspireMD
NSPR
$39.8M
– –
0
– –
CRDC
15
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.38M 1.51%
106,347
– –
HSTO
16
DELISTED
Histogen Inc. Common Stock
HSTO
$1.16M 1.27%
+578
New +$1.07M
RIOT icon
17
Riot Platforms
RIOT
$7.13B
$1.15M 1.25%
73,750
-13,375
-15% -$163K
KBIO
18
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$1.13M 1.23%
31,250
+21,271
+213% +$969K
XNPT
19
DELISTED
XENOPORT, INC.
XNPT
$1.09M 1.19%
191,262
– –
BSTC
20
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.01M 1.1%
51,692
– –
UPI
21
DELISTED
UROPLASTY INC-NEW
UPI
$958K 1.05%
289,332
– –
SPNC
22
DELISTED
Spectranetics Corp
SPNC
$880K 0.96%
52,362
– –
RXII
23
DELISTED
GALENA BIOPHARMA INC COM
RXII
$855K 0.93%
+375,000
New +$855K
PALI icon
24
Palisade Bio
PALI
$349M
– –
0
– –
VXRT
25
DELISTED
Vaxart
VXRT
$845K 0.92%
+18,378
New +$797K
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, DAFNA Capital Management held 57 positions worth $91.5M, up 34% from $68.3M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

DAFNA Capital Management's Q3 2013 filing shows 10 new, 4 increased, 9 reduced and 4 closed positions. Its largest new stake was Ampio Pharmaceuticals Inc.: 1,419 shares worth $3.19M. The largest sale was Novadaq Technologies Inc., an estimated $2.52M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 67% a quarter earlier, followed by Miscellaneous and Financials.

  • DAFNA Capital Management's largest Q3 2013 buy was Ampio Pharmaceuticals Inc.: 1,419 shares worth $3.19M.
  • DAFNA Capital Management added most to Stereotaxis in Q3 2013, an estimated $4.59M increase.
  • DAFNA Capital Management's biggest Q3 2013 reduction was Novadaq Technologies Inc., cutting an estimated $2.52M.
  • DAFNA Capital Management fully exited InfuSystem Holdings in Q3 2013, selling an estimated $707K.
  • DAFNA Capital Management's ten largest holdings make up 59% of its $91.5M portfolio in Q3 2013.
  • DAFNA Capital Management opened 10 new positions and closed 4 in Q3 2013.
  • DAFNA Capital Management's portfolio value rose 34% quarter-over-quarter to $91.5M.

Based on DAFNA Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.